‹ All Posts
Prameela Balakkala

20th Jul · SEBI-Registered Analyst

Rossari Biotech Q1: Growth Amid Margin Pressure

- Q1 revenue rose to ₹697 Cr, up from ₹543 Cr YoY, reflecting robust demand across segments. 💰 Profitability Trends - Consolidated net profit improved to ₹35 Cr versus ₹34 Cr YoY, signaling steady bottom-line growth. - EBITDA increased to ₹81 Cr from ₹68 Cr YoY, driven by operational efficiencies. ⚖️ Margin Watch - EBITDA margin eased to 11.56% from 12.5% YoY, indicating some cost pressures despite higher sales. 🔑 Key Financial Ratios - Return on Capital Employed (ROCE) and Return on Equity (ROE) details will provide deeper insight into capital efficiency. - While revenue and profits are on an upward trajectory, margin contraction calls for close monitoring of input costs and pricing power. - Investors should watch how Rossari balances growth with profitability in a competitive market.

#EquityResearch#Miscellaneous#PsychologyofMoney#PersonalFinance#MacroViews
955 likes·87 comments